Tullika Garg1, Amanda J Young2, Maureen O'Keeffe-Rosetti3, Carmit K McMullen3, Matthew E Nielsen4, Terrence E Murphy5, H Lester Kirchner6. 1. Department of Urology, Geisinger, Danville, PA; Department of Population Health Sciences, Geisinger, Danville, PA. Electronic address: tgarg@geisinger.edu. 2. Biostatistics Core, Geisinger, Danville, PA. 3. Center for Health Research, Kaiser Permanente Northwest, Portland, OR. 4. Department of Urology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC; Department of Epidemiology, Health Policy, and Management, University of North Carolina at Chapel Hill, Gillings School of Global Public Health, Chapel Hill, NC. 5. Section of Geriatrics, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT. 6. Department of Population Health Sciences, Geisinger, Danville, PA.
Abstract
BACKGROUND: Nonmuscle-invasive bladder cancer (NMIBC) disproportionately affects older adults who often have coexisting chronic conditions such as metabolic syndrome (MetS). Although prior research suggests that MetS is a risk factor for NMIBC, limited data exists on whether MetS is associated with NMIBC recurrence. Our objective was to evaluate the association between MetS and recurrence in older adults treated for NMIBC. METHODS: We identified 1,485 older (age ≥60 years) NMIBC patients (American Joint Committee on Cancer Stage ≤1) from 2community-based health systems. Using data from the health systems' electronic medical record, MetS was defined as the presence of three of the following: diagnosis codes indicating hypertension, hyperlipidemia, diabetes, or body mass index >30. Follow up time was determined by date of the last follow up in the tumor registry and censored at 10 years. Cox proportional hazards regression of time to recurrence that accounts for the competing risk of death included adjustment for age, sex, smoking status, health system, NMIBC stage/grade, tumor size, and number of specimens with cancer. RESULTS: Overall, 341 patients (23%) met MetS criteria. Median follow up was 5.9 years and 582 patients (39.2%) died. Patients with MetS were more frequently male (84.2%), and mostly current/former smokers (82.6%). By 10 years, 34.1% of the cohort had experienced a recurrence. After accounting for the competing risk of death, there was no association between MetS and time to recurrence (adjusted hazard ratio, 0.88, 95% confidence interval 0.70-1.11, P = 0.28). Patients without MetS had more 0a/low grade recurrences (49.1% vs. 41.4%), though differences were not significant. CONCLUSION: We found no association between MetS and risk of NMIBC recurrence in this large, multisite cohort of older adults with NMIBC. In order to design personalized care for older NMIBC patients, future research is needed to evaluate associations between common chronic conditions and a variety of oncologic outcomes.
BACKGROUND:Nonmuscle-invasive bladder cancer (NMIBC) disproportionately affects older adults who often have coexisting chronic conditions such as metabolic syndrome (MetS). Although prior research suggests that MetS is a risk factor for NMIBC, limited data exists on whether MetS is associated with NMIBC recurrence. Our objective was to evaluate the association between MetS and recurrence in older adults treated for NMIBC. METHODS: We identified 1,485 older (age ≥60 years) NMIBC patients (American Joint Committee on Cancer Stage ≤1) from 2community-based health systems. Using data from the health systems' electronic medical record, MetS was defined as the presence of three of the following: diagnosis codes indicating hypertension, hyperlipidemia, diabetes, or body mass index >30. Follow up time was determined by date of the last follow up in the tumor registry and censored at 10 years. Cox proportional hazards regression of time to recurrence that accounts for the competing risk of death included adjustment for age, sex, smoking status, health system, NMIBC stage/grade, tumor size, and number of specimens with cancer. RESULTS: Overall, 341 patients (23%) met MetS criteria. Median follow up was 5.9 years and 582 patients (39.2%) died. Patients with MetS were more frequently male (84.2%), and mostly current/former smokers (82.6%). By 10 years, 34.1% of the cohort had experienced a recurrence. After accounting for the competing risk of death, there was no association between MetS and time to recurrence (adjusted hazard ratio, 0.88, 95% confidence interval 0.70-1.11, P = 0.28). Patients without MetS had more 0a/low grade recurrences (49.1% vs. 41.4%), though differences were not significant. CONCLUSION: We found no association between MetS and risk of NMIBC recurrence in this large, multisite cohort of older adults with NMIBC. In order to design personalized care for older NMIBC patients, future research is needed to evaluate associations between common chronic conditions and a variety of oncologic outcomes.
Authors: Asaf Wyszynski; Sam A Tanyos; Judy R Rees; Carmen J Marsit; Karl T Kelsey; Alan R Schned; Eben M Pendleton; Maria O Celaya; Michael S Zens; Margaret R Karagas; Angeline S Andrew Journal: Cancer Date: 2013-10-10 Impact factor: 6.860
Authors: Malte Rieken; Evanguelos Xylinas; Luis Kluth; Joseph J Crivelli; James Chrystal; Talia Faison; Yair Lotan; Pierre I Karakiewicz; Harun Fajkovic; Marek Babjuk; Alexandra Kautzky-Willer; Alexander Bachmann; Douglas S Scherr; Shahrokh F Shariat Journal: BJU Int Date: 2013-12 Impact factor: 5.588
Authors: Tullika Garg; Amanda J Young; Korey A Kost; John F Danella; Sharon Larson; Matthew E Nielsen; H Lester Kirchner Journal: J Urol Date: 2017-08-05 Impact factor: 7.450
Authors: Myrick C Shinall; Shipra Arya; Ada Youk; Patrick Varley; Rupen Shah; Nader N Massarweh; Paula K Shireman; Jason M Johanning; Alaina J Brown; Neil A Christie; Lawrence Crist; Catherine M Curtin; Brian C Drolet; Rajeev Dhupar; Jennifer Griffin; James W Ibinson; Jonas T Johnson; Sonja Kinney; Chad LaGrange; Alexander Langerman; Gary E Loyd; Leila J Mady; Michael P Mott; Murali Patri; Justin C Siebler; C J Stimson; William E Thorell; Scott A Vincent; Daniel E Hall Journal: JAMA Surg Date: 2020-01-15 Impact factor: 14.766
Authors: Andrew M Brunner; Hossein Sadrzadeh; Yang Feng; Benjamin J Drapkin; Karen K Ballen; Eyal C Attar; Philip C Amrein; Steven L McAfee; Yi-Bin Chen; Donna S Neuberg; Amir T Fathi Journal: Am J Hematol Date: 2013-05-30 Impact factor: 10.047
Authors: Benjamin D Smith; Grace L Smith; Arti Hurria; Gabriel N Hortobagyi; Thomas A Buchholz Journal: J Clin Oncol Date: 2009-04-29 Impact factor: 44.544
Authors: Carol E DeSantis; Chun Chieh Lin; Angela B Mariotto; Rebecca L Siegel; Kevin D Stein; Joan L Kramer; Rick Alteri; Anthony S Robbins; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2014-06-01 Impact factor: 508.702
Authors: Patrick O Richard; Ardalan E Ahmad; Shaheena Bashir; Alexandre Zlotta; Bimal Bhindi; Ricardo Leao; Madhur Nayan; Aza Mohammed; Neil E Fleshner; Girish S Kulkarni Journal: Can Urol Assoc J Date: 2018-02-23 Impact factor: 1.862